Suppr超能文献

SCH23390对灌注肾中D1受体介导的血管舒张反应的非典型拮抗作用。

Atypical antagonism of D1-receptor-mediated vasodilator response in the perfused kidney by SCH23390.

作者信息

Martin S W, Broadley K J

机构信息

Department of Pharmacology, Welsh School of Pharmacy, University of Wales Cardiff, Cathays Park, UK.

出版信息

Pharmacol Res. 1995 May;31(5):289-97. doi: 10.1016/1043-6618(95)80034-4.

Abstract

Vasodilator responses to dopexamine, fenoldopam and dopamine, which are known to have agonist activity at D1-dopamine receptors, were examined in the rat isolated perfused kidney preparation. Perfusion pressure was raised by perfusing with the thromboxane TxA2 analogue, U46619, and vasodilator responses were observed as dose-related falls in perfusion pressure. Propranolol (10(-6) M) and prazosin (10(-6) M) were present throughout to eliminate beta 2 and alpha 1-adrenoceptor-mediated responses, respectively. The vasodilator responses were antagonized by SCH23390 (10(-9) M), indicating that they were mediated via D1-receptors. The displacements of the dose-response curves for fenoldopam, dopexamine and dopamine were, however, non-parallel with significant depression of the maxima to 30.2, 37.9 and 34.3%, respectively. In the presence of SCH23390 (10(-8) M) and prazosin (10(-6) M), dopexamine, isoprenaline and noradrenaline produced dose-related renal vasodilation. This was antagonized by propranolol indicating a role for beta-adrenoceptors. In the case of dopexamine, the maximum response was depressed in the presence of propranolol. The reason for the atypical blockade of vasodilator responses by SCH23390 was investigated. One possibility was the appearance of transient vasoconstrictor responses at higher doses of fenoldopam, dopexamine and dopamine, usually preceding the vasodilatation. The possibility was therefore considered that the vasoconstriction may have opposed the usual vasodilation at high doses and thus limited the size of the maximum vasodilation in the presence of SCH23390. The vasoconstriction by fenoldopam was not antagonized by S-sulpiride, the D2-receptor antagonist but was blocked by mianserin and therefore attributed to 5-HT2 receptor stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在大鼠离体灌注肾制备中,研究了对多培沙明、非诺多泮和多巴胺的血管舒张反应,已知这些药物对D1 - 多巴胺受体具有激动剂活性。通过灌注血栓素TxA2类似物U46619来升高灌注压力,并观察到血管舒张反应表现为灌注压力与剂量相关的下降。全程加入普萘洛尔(10⁻⁶ M)和哌唑嗪(10⁻⁶ M)分别消除β₂和α₁ - 肾上腺素能受体介导的反应。血管舒张反应被SCH23390(10⁻⁹ M)拮抗,表明它们是通过D1受体介导的。然而,非诺多泮、多培沙明和多巴胺的剂量 - 反应曲线的位移不平行,最大值分别显著降低至30.2%、37.9%和34.3%。在存在SCH23390(10⁻⁸ M)和哌唑嗪(10⁻⁶ M)的情况下,多培沙明、异丙肾上腺素和去甲肾上腺素产生了与剂量相关的肾血管舒张。这被普萘洛尔拮抗,表明β - 肾上腺素能受体起作用。就多培沙明而言,在普萘洛尔存在下最大反应降低。研究了SCH23390对血管舒张反应非典型阻断的原因。一种可能性是在较高剂量的非诺多泮、多培沙明和多巴胺时出现短暂的血管收缩反应,通常在血管舒张之前。因此认为,血管收缩可能在高剂量时对抗了通常的血管舒张,从而在存在SCH23390时限制了最大血管舒张的大小。非诺多泮引起的血管收缩未被D2受体拮抗剂S - 舒必利拮抗,但被米安色林阻断,因此归因于5 - HT2受体刺激。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验